Industry perspective on life-cycle management
- At: 2017 FIP Congress in Stockholm (Sweden)
- Type: Presentation
- By: HEISTERBERG, Jens (Novo Nordisk, Bagsvaerd, Denmark)
- Co-author(s): Jens Heisterberg: Novo Nordisk, Bagsvaerd, Denmark
Once a medicine is licensed, industry efforts are focussed on securing market access and maximising the commercial value of the product in the period until the expiry of data protection and patents. However, the benefit-risk balance in the narrower, regulatory sense should not be forgotten during the life-cycle. To a large extent, post-licensing.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.